Skip to content
TrialScanner

NCT03493685

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

Phase 3CompletedTVTXLead

Registry record

Lead sponsor
Travere Therapeutics, Inc.
Conditions
Focal Segmental Glomerulosclerosis
Primary completion
Mar 20, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03493685 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.